Clinical Outcomes of Children With Adrenocortical Carcinoma in the Context of Germline TP53 Status. Issue 5 (July 2021)

• Record Type: Journal Article
• Authors: Brenna, Connor T.A.; Michaeli, Orli; Wasserman, Jonathan D.; Malkin, David
• Is Part Of: Journal of pediatric hematology/oncology. Volume 43:Issue 5(2021)
• Publication Date: 2021-07
• Subjects: adrenocortical carcinoma -- TP53 -- p53 -- Li-Fraumeni syndrome -- pediatric; Pediatric hematology -- Periodicals; Tumors in children -- Periodicals; 618.9215
• DOI: 10.1097/MPH.0000000000001982
• Languages: English
• ISSNs: 1077-4114

Abstract

Abstract : Adrenocortical carcinoma (ACC) is a rare, aggressive malignancy of the adrenal cortex. This study characterizes a single-institution cohort of children treated for ACC, and explores the relationship between clinical outcomes of ACC and germline TP53 mutation status. We performed a retrospective chart review of 23 consecutive pediatric patients with ACC treated at The Hospital for Sick Children, Toronto, Canada, between 1977 and 2017. Clinical, biochemical, radiologic, pathologic, and genetic data were collected for each patient. ACC diagnosis followed a bimodal age distribution of 0 to 6 (n=17) and 12+ (n=6) years, with a female:male ratio of 3.6:1. Ten of 20 patients tested for germline TP53 status carried a pathogenic (9) or likely pathogenic (1) variant, including all but 1 male patient. Only 3 patients died of ACC-related causes, each 5 months post-diagnosis. When treated with resection and combination chemotherapy, carriers of germline TP53 mutations may respond more favorably than their wild-type counterparts. In addition, the survival of patients reported in our cohort with high-stage ACC was appreciably greater than previously described (100.0% for stage II, 50.0% for stage III, and 42.9% for stage IV), favoring aggressive intervention in these patient populations. Abstract : Supplemental Digital Content is available in the text.